Getinge AB Class B · OMXSTO:GETI_B
Getinge AB Class B — Q2 2001 Earnings Presentation
29 slides from Getinge AB Class B's earnings presentation, 2001
Slide 1: GETINGE
GETINGE An expanding Medical-Technology group with focus on comprehensive solutions for infection control, surgical systems and care of elderly and disabled people Customers Acute Care Long term care Industry/Laboratories Net Sales ~ 8 billion SEK Associates 5 400 Manufacturing 20 production units i
Slide 2: Business Scope
Business Scope Areas Extended Care Business Areas Infection Control Surgical Systems Sterilisation Hygiene Systems Surgical tables Patient Handling Business Disinfection Wound Care Surgical lamps 40% 30% 30% segments Customer segments Industry Acute care Long term care I0% 60% 30% Customer
Slide 3: Extended Care
Extended Care Hygiene Systems Patient Handling Wound Care Complete solutions for institutional extended care: Nursing Homes, Hospitals, Assisted Living
Slide 4: Extended Care
Extended Care Hygiene Systems Patient Handling Wound Care Market: 1 400 MSEK 1 700 MSEK 8 000 MSEK Growth: 5 - 7 % 8 - 10 % 8 - 10 % Getinge 57% Getinge 37% HillRom US 25% Sakai JP 8% Sunrise, US 12% KCI US 20% Chiltern UK 4% Liko, SE 8% Huntleigh UK 7% France Reval, FR 3% Hoyer, DE 4% Getinge 6%
Slide 5: Extended Care: Strategic Corner-Stones
Extended Care Strategic Corner-Stones Product leadership Complete Solutions Positive outcomes
Slide 6: Business area Extended Care 2001-2002
Business area Extended Care 2001- 2002 A well-positioned business area with increased focus on growth n Strong product pipeline n Cross-selling wound care n Expansion field sale force
Slide 7: Extended Care: Market development Q2
Extended Care Market development Q2 (msek) 2001 2000 Change 2001 2000 Change Orders rcd per market Q2 Q2 H1 H1 USA and Canada 237 187 26% 477 369 29% Great Britain 138 105 31% 344 260 32% Germany 67 58 16% 136 118 15% Other Western Europe 151 108 40% 312 212 47% Rest of the world 22 21 5% 42 34 24%
Slide 8: Extended Care: Results Q2
Extended Care Results Q2 (msek) 2001 2000 2001 2000 2000 Q2 Q2 H1 H1 FY Net sales 629 481 1,293 979 2,111 Gross margin % 48.6% 48.0% 48.8% 49.8% 49.4% Operating cost -227 -171 -437 -346 -719 Operating profit 79 60 193 141 323 Operating margin % 12.5% 12.4% 15.0% 14.4% 15.3%
Slide 9: Infection Control - Health Care
Infection Control - Health Care Disinfection Sterilization IT-solutions Load handling Complete Systems for: Central Processing Departments, Outpatient Surgery, Wards, Infectious Waste, Microbiology, Pharmacies
Slide 10: Infection Control - Industry
Infection Control - Industry Sterilization Washing Water Treatment Load Handling Complete Systems for: Production, Research / Laboratories, Animal Care Facilities, Food Industry
Slide 11: Infection Control
Infection Control Sterilization Disinfection Market: 6 200 MSEK 2 500 MSEK Growth: 4% 5% Getinge 24% Getinge 27% Steris US 21% Miele DE 15% Sakura JP 8% Steris US 9%
Slide 12: Infection Control Health Care: From Product to Solution
Infection Control Health Care From Product to Solution Sterilizer Disinfector Load handling Complete Logistics Infection Information management Control Consumables After Sales service Solutions Education From Cost to Revenue
Slide 13: Infection Control: Strategic Corner-Stones
Infection Control Strategic Corner-Stones Cost leadership Complete Solutions Service Infrastructure
Slide 14: Business area Infection Control 2001-2002
Business area Infection Control 2001- 2002 To create a homogeneous and market oriented organization from a federation of companies acquired in the last I0 years n Improved production structure - cost leadership n Systems sales n Service expansion - infrastructure
Slide 15: Infection Control: Market development Q2
Infection Control Market development Q2 (msek) 2001 2000 Change 2001 2000 Change Orders rcd per market Q2 Q2 H1 H1 Western Europe 374 329 14% 719 653 10% USA and Canada 344 308 12% 643 558 15% Asia/Australia 86 60 43% 149 121 23% Rest of the world 41 34 21% 66 89 -26% Business area total 845 730 16%
Slide 16: Infection Control: Results Q2
Infection Control Results Q2 (msek) 2001 2000 2001 2000 2000 Q2 Q2 H1 H1 FY Net sales 749 722 1,431 1,340 2,935 Gross margin % 36.6% 36.4% 36.1% 37.5% 37.2% Operating cost -210 -173 -402 -343 -722 Operating profit 64 90 115 159 369 Operating margin % 8.5% 12.5% 8.0% 11.9% 12.6%
Slide 17: Business Area Surgical Systems
Business Area Surgical Systems n The infection control market and the market for surgical systems is converging n Getinge will become a more attractive and competent supplier to the healthcare industry n The market for Surgical Systems is to a large extent a fragmented market with further opportunit
Slide 18: Surgical systems
Surgical systems Surgical Tables Surgical Lights Ceiling Service Systems Integrated Solutions for Surgical Workstations and ICU’s
Slide 19: Surgical Systems: ALM acquisition
Surgical Systems ALM was acquired in January 2001 Net sales Appr. 660 Msek Employees 300 Products Surgical lights Surgical tables Ceiling Service Units Distribution Own sales companies in UK, US, France, Italy, Spain and China Distribution and agents in more than 50 countries
Slide 20: Surgical Systems: Maquet acquisition
Surgical Systems Maquet was acquired in December 2000 Net sales Appr. I 400 Msek Employees I 300 Products Surgical tables Infection Control Distribution Own sales companies in Germany, UK, Italy, France, Belgium Japan, USA Distribution and agents in 90 countries
Slide 21: Business Area Surgical Systems: A First Step
Business Area Surgical Systems A First Step n To create o strong global player in the surgical field with world leadership position in: - Surgical tables - Surgical lights - Ceiling Service Units n Distributed through own sales organisation in all major developed markets
Slide 22: Surgical Systems
Surgical Systems Surgical tables Surgical lights Ceiling Service Units Market: 4 000 M 2 000 M 1 000 M Growth: 5% 5% 10 - 15% Getinge 40% Getinge 20% Draeger DE 25% Miizuho JPN 18% Berchtold DE 20% Kreuzer DE 15% Steris US 15% Steris US 15% Getinge 6% Echman UK 7% Heraeus DE 15% Heraeus 5%
Slide 23: Synergies Surgical Systems
Synergies Surgical Systems n Cost synergies of SEK 140 - 150 million annually n Cross-selling => increased sales growth in the years 2 - 5 n Closing down OrtoMaquet will improve the operating profit by SEK 65 million annually
Slide 24: Surgical Systems: Growth Opportunities
Surgical Systems Growth Opportunities n Continuous growth through acquisition principally lights and ceiling service units n Evaluate new areas of interest in the Surgical Systems environment n Develop strong cross selling capabilities n Product innovation - IGS - Endoscopy - Integrated surgical wor
Slide 25: Surgical systems: Market development Q2
Surgical systems Market development Q2 (msek) 2001 2000 2001 2000 Orders rcd per market Q2 Q2 H1 H1 USA and Canada 107 13 206 53 Great Britain 19 0 65 0 Germany 167 0 316 0 Other Western Europe 214 0 340 0 Rest of the world 134 18 254 22 Business area total 640 30 1,181 75
Slide 26: Surgical systems: Results
Surgical systems Results Q1(msek) 2001 2000 2001 2000 2000 Q2 Q2 H1 H1 FY Net sales 534 36 1,090 70 147 Gross margin % 50.5% 25.0% 49.1% 29.8% 30.2% Operating cost -207 -11 -412 -23 -45 Operating profit 63 -2 123 -2 -1 Operating margin % 11.7% -4.5% 11.3% -3.0% -0.7%
Slide 27: Getinge Group Objectives
Getinge Group Objectives n To retain and develop world leadership position in prioritized business areas / business niches n Growth in profit before tax of I5% over a business cycle n Organic growth 5 % n Internally generated cash flow to sustain an external growth rate of I0 %
Slide 28: Getinge Industrier Q2 Results
Getinge Industrier Q 2 Results msek 2001 2000 Change 2001 2000 Change 2000 Q2 Q2 H1 H1 FY Orders received 2,114 1,252 69% 4,100 2,519 63% 5,243 Net sales 1,926 1,252 54% 3,845 2,420 59% 5,254 EBITDA 297 195 52% 612 394 55% 892 Operating profit 206 149 38% 434 301 44% 697 Operating margin 10.7% 11.9%
Slide 29: Getinge Industrier Balance sheets
Getinge Industrier Balance sheets msek Assets 2001-06-30 2000-06-30 2000-12-31 Intangible fixed assets 2,770 1,003 2,451 Tangible fixed assets 1,326 756 1,228 Financial assets 414 125 391 Stock-in-trade 1,770 892 1,269 Current receivables 2,645 1,625 2,457 Liquid funds 442 226 235 Total assets 9,366